Canopy Growth: Penny Stock Purgatory -- or Cannabis Rebound in the Making?

Canopy Growth (NASDAQ: CGC) has spent the better part of the past five years destroying shareholder value. The stock is down more than 99% from its all-time high. The company has burned through billions of dollars, diluted shareholders repeatedly, exited non-core businesses, and cycled through multiple restructuring efforts. So why is it even worth discussing?

Today's Canopy looks very different from the company that chased global expansion at any cost. It's worth taking a closer look to see if the business has finally reached a point where the fundamentals are beginning to improve.

Getting leaner

For years, Canopy tried to be everything at once. It invested heavily in production capacity, acquired companies around the world, launched consumer packaged goods, entered the sports nutrition business through BioSteel, and spent aggressively on U.S. cannabis options.

Much of that strategy failed. Today, management is taking a much more disciplined approach. BioSteel is gone. The company has dramatically reduced operating expenses, streamlined production, strengthened its Canadian cannabis brands, and shifted more of its attention toward higher-margin medical cannabis markets.

Canopy also completed its acquisition of MTL Cannabis, strengthening its position in both the Canadian recreational and medical markets. Those changes don't guarantee success, but they do create a business that's easier to analyze than the sprawling organization the market saw several years ago.

The balance sheet looks better than it has in years

One of the biggest concerns surrounding Canopy has always been cash. Repeated operating losses forced the company to issue stock, sell assets, and restructure its debt. Earlier this year, however, Canopy completed a major recapitalization that significantly reduced its debt burden. The company finished fiscal 2026 (ended June 30) with about $131.3 million in net cash, giving management additional financial flexibility after years of balance sheet pressure.

So now, instead of focusing primarily on survival, management can devote more attention to improving operations and expending the underlying business. To be sure, the company still isn't consistently profitable, but the financial picture is considerably healthier than it was just a few years ago.

Medical cannabis advantage

Another notable shift is where Canopy expects future growth. Canada's recreational cannabis market remains highly competitive, with endless pricing pressure limiting profitability across the industry. The medical cannabis market, however, is a completely different story.

During fiscal 2026, Canopy reported 27% fourth-quarter revenue growth in Canadian medical cannabis and 68% growth in international medical cannabis, reflecting continued expansion in markets such as Germany, where demand has accelerated after regulatory reforms.

Medical markets generally offer better pricing and fewer competitors than recreational-use retail markets. That doesn't eliminate execution risk, but it does provide a clearer path toward sustainable margins.

Image source: Getty Images.

The risks haven't disappeared

Despite the progress, you shouldn't ignore the remaining challenges. Canopy is still losing money. Its U.S. strategy remains tied to federal cannabis legalization, and although Canopy USA now owns businesses such as Acreage, Wana, and Jetty, Canopy Growth no longer consolidates those operations into its financial statements. The value of those investments will depend heavily on future regulatory developments and the financial performance of Canopy USA itself.

Competition also remains intense. The Canadian cannabis market continues to suffer from oversupply, price compression, and a large number of licensed producers competing for market share. Those industrywide challenges aren't going away anytime soon.

Is Canopy finally becoming investable?

Canopy Growth probably isn't ready to be considered a turnaround success. The company still has a great deal to prove, beginning with consistent revenue growth, improved margins, and ultimately sustainable profitability.

But this is no longer the same company of three or four years ago. Management has simplified the business, strengthened the balance sheet, and shifted its focus toward markets where pricing and long-term demand appear more attractive.

So if you're willing to accept significant risk, that may be enough to justify another look. If not, patience may still be the better strategy. The turnaround is becoming more credible, but it hasn't been completed yet.

Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.